Clinical Trial Update: Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AVE1625 as a co-treatment with antipsychotic therapy for schizophrenia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• AVE1625

Snippet

Sponsor: Sanofi | Conditions: Schizophrenia | Phase 2 | Status: TERMINATED